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Prostate cancer is one of the most common cancers among men in
many Western countries, including Finland. However, the molec-
ular genetic events associated with the development and progres-
sion of the disease are poorly known. According to the multistep
model of carcinogenesis, several genetic aberrations take place in
prostate cancer, but only a few genes potentially involved in
prostatic carcinogenesis have been identified.
It has been suggested that genetic alterations take place in
several chromosomal regions in prostate cancer and, in compara-
tive genomic hybridization (CGH) studies, the long arm of chro-
mosome 16 is among those showing the most frequent loss (Joos
et al, 1995; Visakorpi et al, 1995; Cher et al, 1996). Losses at chro-
mosome 16 have been reported to occur almost exclusively in the
long arm (q) (Bergerheim et al, 1991; Visakorpi et al, 1995; Cher
et al, 1996). Both primary and metastatic tumours have been found
to show allelic loss at 16q, and the occurrence of loss of heterozy-
gosity (LOH) has also been associated with clinicopathological
variables such as aggressive and metastatic behaviour of the
disease and poor differentiation of the tumour (Carter et al, 1990;
Suzuki et al, 1996; Elo et al, 1997; Latil et al, 1997). The most
common area of deletion has been suggested to be distal in 16q,
but the most recent results have indicated evidence of loss of
several independent regions in 16q (Suzuki et al, 1996; Elo et al,
1997; Latil et al, 1997).
Particular interest in losses at 16q has been paid to the region
16q21.1, where a potential tumour-suppressor gene, that for E-
cadherin, is located. Decreased E-cadherin expression has been
associated with poor prognosis of prostate cancer (Umbas et al,
1994). Recently, the regions of loss at chromosome arm 16q have
been narrowed down. It has been suggested in several reports that
losses at 16q are concentrated in three independent regions
(Suzuki et al, 1996; Latil et al, 1997). The proximal area of loss is
suggested to be located somewhere at 16q21.1 and the distal area
of loss has been suggested to lie at 16q24.3. The central region of
loss has been reported to be at 16q23.2 (Latil et al, 1997), but it has
also been reported to be located at 16q23.2–q24.1 (Suzuki et al,
1996). Our recent data indicate that a 7.6-cM central area of loss is
located at 16q24.1–q24.2, between markers D16S504 and
D16S422. In addition, LOH at 16q24.1–q24.2 (HSD17B2 and
D16S422) was found to be the most frequent area of deletion, and
it was significantly correlated with aggressive and metastatic
behaviour of the disease and also with poorly differentiated
tumours (Elo et al, 1997).
There are several candidate genes putatively involved in
prostatic carcinogenesis located distally at 16q. The 17HSD type 2
gene (HSD17B2), located at 16q24.1–q24.2, encodes the 17b-
hydroxysteroid dehydrogenase (17HSD) type 2 isoenzyme, which
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has been reported to inactivate active androgens in prostatic
epithelial cells and is, thus, suggested to protect them from exces-
sive androgen action (Délos et al, 1995; Durocher et al, 1995; Elo
et al, 1996). The genes for three cell adhesion-regulating mole-
cules are also reported to be located at 16q24. The cell adhesion
regulator gene is located at 16q24 (Pullmann and Bodmer, 1992).
Decrease of its expression could be involved in decreased tumour
invasion suppression. The genes of two members of the cadherin
superfamily, M-cadherin and H-cadherin, are located at 16q24
(Kaupman et al, 1992; Lee, 1996) and the expression of H-
cadherin has been reported to be decreased in breast tumours (Lee,
1996). C-myc promoter-binding protein, whose gene is another
possible target, is located at 16q24 and it is a negative regulator of
c-myc oncogene expression (Ray and Miller, 1991).
In the present study, LOH at chromosome arm 16q was studied
in 44 prostatic cancer patients exhibiting various clinical features.
Fifteen polymorphic polymerase chain reaction (PCR) markers
were used to identify the separately deleted areas, and the findings
were compared with clinicopathological variables and the 5-year
survival rate of the patients. Exons 1–3 and 6–7 of the gene
HSD17B2, coding for active 17HSD type 2 enzyme, were
sequenced using tissues from 20 patients showing LOH at
16q24.1–q24.2.
MATERIALS AND METHODS
Subjects and specimens
Allelic losses at chromosome arm 16q were studied in tissues from
44 prostate cancer patients undergoing radical prostatectomy or
transurethral resection of the prostate. The patients were classified
according to the TNM classification system (T1M0, three patients;
T2M0, six patients; T3M0, 13 patients; T4M0, nine patients;
T3M1, eight patients; T4M1, five patients) (Chisholm, 1988).
Digital rectal examination, transrectal ultrasonography, bimanual
palpation and cystoscopy were used when determining the T-stage.
The M-stage was determined in all the patients by bone scanning,
thorax radiograph and ultrasound examination of the abdomen; to
determine the N-stage, staging pelvic lymphadenectomy was
carried out only when radical operation was performed. Twenty of
the patients were operated upon because of recurrent disease after
endocrine therapy and the remaining twenty-four patients in the
study had primary tumours. Tumours without local progression or
metastases and all grade 1 tumours were considered clinically to
be non-aggressive (26 patients). The disease of 18 of the patients
was considered clinically aggressive.
The specimens were histologically confirmed to contain at least
60% malignant cells. After dissecting the specimens from paraffin
blocks, the DNA was extracted using a standard protocol (Wright
and Manos, 1990). For controls, DNA obtained from benign
prostatic tissue of the same patient was used.
PCR and fragment analysis
Fifteen microsatellite markers (D16S408, D16S514, D16S503,
D16S512, D16S515, D16S516, D16S504, D16S511, HSD17B2,
D16S422, D16S3061, D16S520, D16S476, D16S3028 and
D16S413) spanning chromosomal arm 16q and their corre-
sponding PCR primers were chosen from the Genethon compre-
hensive genetic map (Dib et al, 1996) or from the Genomic
Data Base (http://gdbwww.gdb.org/). The 25-ml PCR mixtures
contained 100 ng template DNA, 50 pmol each of two primers
(one of them fluorescently labelled; Pharmacia LKB Bio-
technology), 200 mmol of each deoxy-NTP (Pharmacia LKB
Biotechnology), Reaction Buffer IV (Advanced Biotechnologies),
1m M magnesium chloride (Advanced Biotechnologies) and
0.25 U of Red Hot DNA-polymerase (Advanced Biotechnologies).
According to the hot start protocol, the reaction mixtures were first
denatured at 95°C for 5 min, after which the DNA polymerase was
added. Thirty-five PCR cycles were then carried out (GeneAmp
9600 thermal cycler, Perkin Elmer Cetus) using the following
steps: denaturing at 95°C for 1 min, annealing at 55–65°C (opti-
mized separately for each primer pair) for 1 min, and amplification
at 72°C for 2 min. Lastly, a 7-min final extension at 72°C was
carried out. To determine the sizes of the alleles and the loss of
heterozygosity, the fluorescent PCR products were loaded on a 5%
Long Ranger gel (FMC BioProducts) in the presence of Prism
Genescan-500 Tamra allelic size markers (Applied Biosystems)
and run for 4 h in an ABI 377 sequencer utilizing GeneScan soft-
ware (Applied Biosystems). The data obtained were analysed by
using Genotyper software (Applied Biosystems). Analysis of LOH
was carried out by calculating the ratio of the constituent alleles, as
reported previously (Canzian et al, 1996; Elo et al, 1997). When
one of the alleles was decreased by at least 40%, the specimen was
considered to show LOH. An example of representative results
obtained is shown in Figure 1.
Direct sequencing
In twenty specimens showing LOH at 16q24.1–q24.2, the exons of
HSD17B2 coding for the active enzyme were sequenced. The
primers used for amplication of exons 1–3 and 6–7 encoding
17HSD type 2 were designed on the basis of the nucleotide
sequence of HSD17B2 (Labrie et al, 1995). PCR amplification was
performed as described for LOH analysis above, except that the
magnesium chloride concentration was increased to 1.5 mmol l–1,
and the dNTP and primer concentrations were decreased to
0.08 mmol l–1 and 20 pmol l–1 respectively. The PCR products
were purified from excess primers and nucleotides by using a
single-step ExoI/SAP method (Werle et al, 1994).
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Figure 1 An example of a prostate cancer specimen showing loss of
heterozygosity at 16q24.1–q24.2 (HSD17B2) and retained heterozygosity at
16q24.3 (D16S3028). Fragment size is indicated in the upper box and the
area of the peak in the lower box158 JP Elo et al
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Cycle sequencing reactions using an Abi Prism dRhodamine
Terminator Cycle Sequencing Ready Reaction Kit were carried out
in a total reaction volume of 20 ml, as suggested by the manufac-
turer (Applied Biosystems). The extension products were purified
by using an ethanol/sodium acetate precipitation procedure and the
samples were prepared according to the instructions of the manu-
facturer (Applied Biosystems). In gel electrophoresis, the samples
were loaded on a 5% Long Ranger gel (FMC Bio Products) and
run in the Abi Prism 377 DNA Sequencer (Perkin Elmer Cetus).
The results obtained were analysed using DNA Sequencing
Analysis 2.1.1 software (Applied Biosystems).
Statistical analysis
Two-tailed Fisher’s exact tests (SPSS for Windows, SPSS) were
used to analyse the associations between loss of heterozygosity
and the clinicopathological parameters. In addition, backward
step-wise logistic regression analysis (SPSS for Windows, SPSS)
was used in testing the associations, and the survival analyses were
carried out by using the Kaplan–Meier test (SPSS for Windows,
SPSS). A P-value of < 0.05 was considered as significant.
RESULTS
Regions of common allelic loss were studied in 44 prostatic cancer
specimens and in corresponding benign specimens, using 15
microsatellite markers. Twenty-two of the specimens (50%)
showed LOH at chromosome arm 16q, 15 of the specimens (34%)
showed partial loss at 16q, whereas seven of the specimens (16%)
showed complete loss of the segments studied. The data indicated
that there are at least three independently deleted regions, as
reported previously. In the present study, the most proximally
located 1.8-cM area of loss was at 16q21.1 (region A), between
markers D16S514 and D16S503; the central 7.6-cM area of dele-
tion was at 16q24.1–q24.2 (region B) between markers D16S504
and D16S422; and the most distal area of common deletion was
located at 16q24.3–qter (region C), distal to marker D16S3028
(Figure 2A and B).
Of the three independently deleted areas, region A showed LOH
in 14 (32%), region B in 19 (43%) and region C in 16 (36%) of
the specimens studied. The most commonly deleted individual
markers, D16S422 (48%, 15/31) and HSD17B2 (52%, 16/31),
were located within region B. Among the cancer death cases, LOH
at 16q was found in 63% (12/19) of the specimens. The 13
metastatic disease showed LOH at the three independent regions in
31% (region A) to 62% (region B) of the specimens. Similarly, the
frequency of losses at the separate regions in aggressive diseases
varied from 43% (region A) to 67% (region B) of the specimens.
The frequency of losses at the independently deleted regions
was further compared with the clinicopathological variables. The
data indicated that losses at regions A, B and C were significantly
associated with aggressive behaviour of the disease (A, P < 0.05;
B, P < 0.01; C, P <0.05). In addition, losses at region B were
significantly associated with poorly differentiated tumour cells
(P < 0.05) and with recurrent (P < 0.01) growth of the tumour.
Step-wise logistic regression analysis showed that aggressive
behaviour of the disease and recurrent growth were correlated
significantly with the appearance of LOH at region B (P < 0.01).
Recurrent growth was associated with an approximately sixfold
increase in the occurrence of LOH, and aggressive disease was
associated with a sevenfold increase in the appearance of LOH.
During the 5-year follow-up period, 28% of the patients initially
with M0 disease developed distant metastases. Of the M0 patients
showing LOH at region B, 45% developed metastases, and metas-
tases were found in 28% of the patients showing LOH at region A.
Interestingly, only 17% and 19%, respectively, of the patients with
retained heterozygosity at these two regions developed metastatic
disease. After the 5-year follow-up period, 14 (32%) of the
patients remained alive, whereas 19 (43%) had died as a result of
their prostate cancer and 11 (25%) had died as a result of another
Figure 2 (A) Deletion map of the tumours showing partial LOH at
chromosome arm 16q. (l l) Retention of heterozygosity; (l) loss of
heterozygosity; (l) homozygote. The data indicate that there are at least
three independently deleted regions at 16q. The proximal area of common
loss is at 16q21.1 (D16S514–D16S503), the central area of deletion is at
16q24.1–q24.2 (D16S504–D16S422) and the distal region is at 16q24.3–qter
(D16S3028–qter). The central region is further suggested to be the most
commonly deleted independent area of deletion. (B) Percentage of prostate
cancer specimens showing allelic loss of the markers studied. The most
commonly deleted markers were HSD17B2 (52%) and D16S422 (48%),
located at 16q24.1–q24.2
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cause. The overall survival rate of the patients showing allelic loss
at regions A and B was significantly lower than that of the patients
with retained heterozygosity (Figure 3). In addition, the survival
rate of the patients with recurrent disease and showing allelic loss
at region B was significantly lower (P= 0.041; Breslow test) than
that of the patients with recurrent disease, but retained heterozy-
gosity. Sequencing analysis of the coding regions of HSD17B2
revealed no amino acid-changing point mutations.
DISCUSSION
Deletion mapping of the long arm of chromosome 16 indicated
loss at three independent regions at least, as reported previously in
two separate studies (Suzuki et al, 1996; Latil et al, 1997). The
proximal area of deletion in the present study was located
at 16q21.1 (region A), whereas the central area was located at
16q24.1–q24.2 (region B) and the distal area was located at
16q24.3–qter (region C). There is consistency as regards the loca-
tion of frequent loss at 16q21.1 between studies, but results
concerning the central area are more controversial. Our previous
data indicated a common area of loss located centrally at
16q24.1–q24.2, between markers D16S504 and D16S422. The
central area bracketed by Latil et al (1997) was located at 16q23.2,
and Suzuki et al (1996) located the central area at 16q23.2–q24.1.
Data from previous studies agree as regards the location of the
third and most distal area of deletion as being from 16q24.3 to qter.
The deletion pattern observed in 16q in the present study
indicates that the most commonly deleted individual markers
(D16S422 and HSD17B2) were located within region B. The same
markers were also the most commonly deleted in our previous
study, and, in addition, loss at the region was associated with
aggressive features of the disease (Elo et al, 1997). Although the
number of patients studied was relatively small, the findings were
compared with the clinicopathological features. The association
between loss at region B and clinically aggressive features of the
disease, suggested in our previous study, was confirmed. Loss at
region B was found to be significantly correlated with poor differ-
entiation of the tumour cells, aggressive behaviour of the disease
and recurrent growth of the tumour at the time of obtaining the
specimen. Interestingly, losses at regions A and C were associated
only with aggressive behaviour of the disease.
The frequent occurrence of common areas of loss at 16q is of
particular interest because of the clinical associations and the iden-
tification of several genes putatively involved in prostatic carcino-
genesis (Carter et al, 1990; Visakorpi et al, 1995; Suzuki et al,
1996; Elo et al, 1997; Latil et al, 1997). Loss at 16q24.1–q24.2
separately from the distal region at 16q24.3–qter further supports
the idea of the existence of at least two different genes putatively
involved in prostatic carcinogenesis located distally at chromo-
some arm 16q. Despite the identification of some of the genes
located at frequently deleted regions, none of the candidate genes
have been confirmed to be the main target of the losses observed.
The genes for at least two different adhesion molecules are located
at 16q24. M-cadherin, whose gene is located at the central region
of loss, is a member of the superfamily of cell adhesion molecules.
Interestingly, the gene for another cell adhesion molecule, H-
cadherin, the decreased expression of which has been reported in
breast cancer tissue, is located at 16q24 (Lee, 1996). The cell
adhesion regulator gene is located at 16q24.3, within the distal
region of common loss. In addition to the cell adhesion molecule
genes, that for c-mycpromoter-binding protein, which regulates
the expression of the c-myconcogene, is also located at 16q24
(Ray and Miller, 1991). The gene HSD17B2, located at
16q24.1–q24.2, is also a gene of interest. The gene encodes the
enzyme 17HSD type 2, which inactivates the active androgens
testosterone and 5a-dihydrotestosterone into their less active
metabolites androstenedione and 5a-androstenedione respectively.
Sequencing of the exons coding for active 17HSD type 2 showed
no amino acid-changing point mutations, but it is still possible that
mutations affecting the transcriptional activity of the gene are
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Figure 3Kaplan–Meier overall survival rates of the 44 prostate cancer
patients exhibiting various clinical features, related to LOH detected.
(A) Region A (16q21.1; P = 0.014, Breslow test), (B) region B
(16q24.1–q24.2; P = 0.011, Breslow test) and (C) region C (16q24.3–qter;
P= 0.072, Breslow test)160 JP Elo et al
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located at the promoter area not analysed in the present study. In
addition, the possible methylation sites of HSD17B2 are not
known. A decrease in the expression of 17HSD type 2 could lead
to increases in the concentrations of active androgens in the
prostate and, thus, result in an increase in proliferative pressure as
a consequence of the presence of active androgens in the prostatic
epithelium. The expression of 17HSD type 2 mRNA is reported to
be lower in prostate cancer tissues, when compared with that in
hyperplastic prostate tissue (Elo et al, 1996). In addition, 17HSD
activity has been reported to be lower in a group of patients with
poor responses to androgen ablation therapy (Brendler et al, 1984).
It has been suggested that allele loss could lead to decreased gene
expression as a result of the ‘genetic dosage’ effect (Vogelstein and
Kinzler, 1992; Isaacs, 1994). The frequent LOH detected at
16q24.1–q24.2 could be one explanation for the decreased 17HSD
mRNA expression and 17HSD activity detected in prostate cancer
specimens (Brendler et al, 1984; Klein et al, 1991; Elo et al, 1996).
The present data further confirm the existence of at least three
independently deleted regions at 16q. It is, therefore, suggested
that several important genes regarding prostate cancer are located
at chromosome arm 16q and in particular at 16q24.1–q24.2.
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